ABSTRACT
The purpose of current study is to understand trucking industry and challenges associated with its operation and transform trucking industry through Digital Transformation taking help from Digital India Program started by Government of India to enhance digital transformation given its impact on operation efficiency of various businesses in general and trucking industry in particular with special reference to its operational efficiency. Having look at current scenario of trucking industry with reference to nature of operation, ownership profile, areas of operation, regulatory and legislative measures relating to trucking industry, enroute operation challenges, higher operating cost and delays in operation, and many more are not allowing the trucking industry to enjoy economies of scale with special reference to small operators. Thus, in other words, the study found that trucking operation has numerous challenges which hampers the growth of the sector as observed during conduct of the study. However, through penetration of technology via digital transformation in trucking segment especially with reference to its operation in particular we can provide some good relief and can transform the trucking sector into most appropriate segment from viability of operation i.e. operational efficiency. The major implication of the study is that the result is based on limited data and information due to Covid-19 pandemic (Second Wave). Nevertheless, this can form basis to understand the process of digital transformation and its application to transform trucking operation to solve its operational issue and many more. The utility of the study can be derived from the point that this paper is one of the few studies conducted recently that provides insight into process of transforming trucking industry through digital transformation and possible economic benefits derived from digital transformation. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
ABSTRACT
The new coronavirus, which produces a highly contagious sickness, enters the picture. Globally, the coronavirus disease (COVID-19) has boosted the use of Internet commerce. It has resulted in an increase in the number of FTUs, or first-time e-commerce users, in India, who were previously unable to purchase online. Customers are depending on Amazon more than ever before in their social isolation and self-quarantine attempts, according to Amazon, one of the country’s and the world’s major e-commerce businesses (https://retail.economictimes.indiatimes.com/re-tales/impact-of-covid-19-on-onlineshopping-in-india/4115 ). The goal of this study is to determine the elements that influence customers’ online purchases of mobile phones, as well as how that practice has altered since the global COVID-19 outbreak. An online survey was done, and data were gathered from primary sources to interpret the objectives. The goal of the study is to figure out how successful online advertising is at raising awareness and what the link is between Internet advertising and purchasing decisions. © 2023, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
ABSTRACT
Introduction: Pomalidomide is a third-generation immunomodulatory drug approved for relapsed and/or refractory Multiple Myeloma (RRMM). In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone demonstrated superior efficacy in patients with RRMM. PRIME study (CTRI/2019/10/021618) is testing this combination in Newly Diagnosed Multiple Myeloma (NDMM) Aim: To determine safety of Pomalidomide in combination with Bortezomib and dexamethasone (VPD) in NDMM Study design: A prospective, single arm, phase II study from a tertiary center. Both transplant eligible and ineligible patients with NDMM aged between 18-70 years are being recruited in the study. Patients with Plasma cell leukemia, POEMS and amyloidosis were excluded. The regimen consists of weekly Bortezomib 1.3mg/sq.m (subcutaneous), Tab. Pomalidomide 2-4mg once daily for 21days, and Tab Dexamethasone 20mg twice weekly, with the cycle repeating every 28 days, 9-12 cycles. Here we report the adverse events (AE) by NCI CTCAE v5.0, upon recruiting 26 patients, as predetermined in the study. Results: Of the proposed 45-50 patients, 26 patients were enrolled in the study between April 2020 to May 2021 and 23 (88.4%) have completed 4 cycles of VPD. The median age is 55years (18-70), and gender ratio 1:1. At disease presentation, bone lesions were the commonest (96.2%, n=25), IMWG high risk cytogenetics were seen in 42.4% (n=11), RISS-2 in 69.3% (n=18), IgG kappa paraproteinemia in 54% (n=14) patients and ECOG performance score 2-3 in 57.6%(n=15). Ten (38.5%) patients have completed 9 cycles, and 3 underwent auto-transplant (between Cycle 4 & 6). Protocol adherence was 96.1% (25/26 patients). Table-1 shows drug-induced toxicity, hematological toxicities were the commonest. Two patients withdrew consent in view of bortezomib-induced peripheral neuropathy. Serious adverse events (SAE) were reported in 9 (34.6%) patients and were considered unrelated to the regimen by the safety committee (PSVT=1, Bony pain=2, dyspnea=1, pneumonia=1, constipation=1, diarrhea=1, hypotension=1) and one death due to SARS-CoV2 pneumonia. Treatment delays of 2 weeks in 4 patients (SARS-CoV2 = 3, Syncope = 1) After 4 cycles (n=23), 6 (26%) patients were in stringent Complete Response (sCR), 17(74%) in Very Good partial response (VGPR) and 13 (56.5%) are Measurable Residual Disease (MRD) negative. Of 10 patients who completed cycle 9, 9 were MRD negative and 1 showed disease progression. Conclusion: Safety data from the PRIME study demonstrates that VPD regimen has a favorable tolerance profile in patients with NDMM. Early efficacy signals are encouraging, and recruitment continues. [Formula presented] Disclosures: Radhakrishnan: Dr Reddy's Laboratories: Honoraria, Membership on an entity's Board of Directors or advisory committees;Emcure Pharmaceuticals: Research Funding;Intas Pharmaceuticals: Research Funding;Janssen India: Honoraria;NATCO Pharmaceuticals: Research Funding;Novartis India: Membership on an entity's Board of Directors or advisory committees;Roche India: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding;AstraZeneca India: Honoraria, Speakers Bureau;Bristol-Myers-Squibb India: Membership on an entity's Board of Directors or advisory committees, Research Funding;Cipla Pharmaceuticals India: Research Funding;Aurigene: Speakers Bureau. Garg: Dr Reddys Laboratories: Honoraria, Speakers Bureau. Nair: Dr Reddy's Laboratories: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau;Intas pharmaceuticals: Honoraria, Speakers Bureau;Mylan pharmaceuticals: Honoraria;Novartis India: Honoraria;Fresenius Kabi India: Honoraria;Cipla Pharmaceuticals: Honoraria, Speakers Bureau;Janssen India: Honoraria, Speakers Bureau. Chandy: Janssen: Honoraria;Pfizer: Honoraria;Intas Pharmaceuticals: Research Funding.
ABSTRACT
Aims & Objectives: We conducted a clinical audit of patients with hematological disorders and SARS-CoV2 infection. Patients/Materials & Methods: A prospective registry was established in April 2020 for patients from the department of clinical hematology and HCT who were diagnosed to be positive for SARSCoV2 by PCR test. Out patients creening was symptom/contact-exposure driven, and in patients creening was symptomaticorpreemptive. This study is a part of ASHCOVID19 International collaborative and an interim analysis of the institute registry data from April 15, 2020 to October 7, 2020. Results: 1201 new patients were registered and 9539 patient-visits were recorded in the out patient service of the department during this period. 91 (0.08%) patients tested positive for SARS-CoV2. Baseline characteristics of the patients are listed in Table 1. 56 (61.5%) patients needed hospitalization. The median absolute neutrophil count was 3700/cu.mm, while the median absolute lymphocyte count 900/cu.mm. Inflammatory markers (n = 21):median D-dimer was 2845 ng/ml (243-140643) and median CRP level was 14 mg/dl (3.3- 34). Therapy directed against SARS-CoV2 included, Azithromycin (n = 52,60.4%), Dexamethasone (27 patients,29.7%), Remdesivir (n = 10,11.1%) and doxycycline (n = 9,9.9%). 2(2.2%) patients received tocilizumab and 1 patient (1.1%) received convalescent plasma. On univariate analysis, none of the therapies seemed to affect outcomes. The SARS-CoV2 infection mortality was 15% (14/91). 2 patients died due to non-COVID related causes [tumor lysis syndrome (n = 1), leukocytostasis with CVA (n = 1)]. 7/45(15.5%) receiving anti-B-lymphocyte directed therapy died as compared to 7/46(15.21%) not receiving Anti-B-cell therapies. Patients with low grade B-NHL (5/16,31.25%) had the highest mortality rate followed by high grade B-NHL (7/23,30.4%).There was a trend to higher mortality in patients>50 years (12/45,26.6% in those[=50 years age as compared to 4/30,13.33% in those<50 years age). With data available until the date of censoring, most patients were diagnosed in August (n = 32,35.2%) with numbers tailing off in September (n = 20, 22%). Discussion & Conclusion: In our subset of patients with hematological disorders, SARS-COV2 infectivity was found to be low, hospitalization rate was moderate, and mortality was high and commoner in patients>50 yr and a B-cell lymphoma diagnosis. A more aggressive screening approach will potentially improveoutcomes.